⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
High fills per patient
Risk indicators are statistical patterns, not allegations. Learn more
24,505
Total Claims
$1.6M
Drug Cost
939
Beneficiaries
$1,675
Cost/Patient
Risk Score Breakdown 3/100
Low (0)Moderate (15)Elevated (30)High (50+)
High fills per patient+3
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+19%
Cost per patient vs peers
$1,675 vs $1,411 avg
+9%
Brand preference vs peers
11.6% vs 10.6% avg
Brand vs Generic
88% generic
Brand: 2,842 claims · $1.3M
Generic: 21,622 claims · $302K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Rivaroxaban | 585 | $385K |
| Apixaban | 277 | $179K |
| Empagliflozin/Linagliptin | 139 | $100K |
| Sitagliptin Phosphate | 117 | $78K |
| Evolocumab | 87 | $53K |
| Insulin Glargine,hum.Rec.Anlog | 62 | $48K |
| Sitagliptin Phos/Metformin Hcl | 54 | $40K |
| Sacubitril/Valsartan | 60 | $40K |
| Candesartan/Hydrochlorothiazid | 303 | $36K |
| Sitagliptin Phos/Metformin Hcl | 47 | $31K |
| Dapagliflozin Propanediol | 43 | $30K |
| Levothyroxine Sodium | 522 | $30K |
| Empagliflozin | 44 | $30K |
| Linagliptin | 56 | $30K |
| Insulin Nph Hum/Reg Insulin Hm | 66 | $27K |
Prescribing Profile
Patient Profile
75
Avg Age
55%
Female
2.03
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About